Venclexta (venetoclax tablets) — Cigna

Initial criteria

• Patient age ≥ 18 years
• Patient has tried at least one systemic regimen OR (patient has a TP53 mutation AND medication is used as induction therapy in combination with Brukinsa (zanubrutinib) and Gazyva (obinutuzumab))

Approval duration

1 year